Novo Nordisk A/S $NVO Shares Bought by Teamwork Financial Advisors LLC

Teamwork Financial Advisors LLC lifted its holdings in Novo Nordisk A/S (NYSE:NVO) by 233.9% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 98,666 shares of the company’s stock after purchasing an additional 69,120 shares during the quarter. Teamwork Financial Advisors LLC’s holdings in Novo Nordisk A/S were worth $5,020,000 as of its most recent filing with the SEC.

A number of other large investors also recently modified their holdings of NVO. Franklin Resources Inc. grew its position in Novo Nordisk A/S by 4,190.8% in the 3rd quarter. Franklin Resources Inc. now owns 13,984,789 shares of the company’s stock valued at $776,016,000 after buying an additional 13,658,867 shares in the last quarter. Capital International Investors raised its position in shares of Novo Nordisk A/S by 52.4% during the 3rd quarter. Capital International Investors now owns 17,713,424 shares of the company’s stock worth $982,969,000 after buying an additional 6,092,192 shares in the last quarter. Boston Partners bought a new stake in shares of Novo Nordisk A/S during the 3rd quarter worth about $310,199,000. SG Americas Securities LLC lifted its stake in shares of Novo Nordisk A/S by 2,101.5% in the 3rd quarter. SG Americas Securities LLC now owns 2,383,176 shares of the company’s stock worth $132,242,000 after acquiring an additional 2,274,925 shares during the period. Finally, Clear Street Group Inc. bought a new position in shares of Novo Nordisk A/S in the third quarter valued at approximately $56,378,000. 11.54% of the stock is owned by institutional investors and hedge funds.

Novo Nordisk A/S News Roundup

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: FDA approves higher‑dose Wegovy (semaglutide 7.2 mg, “Wegovy HD”) with strong STEP UP trial weight‑loss results (~20.7% mean weight loss); company plans a U.S. launch in April—this supports revenue and market share recovery vs. Lilly. Reuters: Novo Nordisk wins U.S. nod for higher-dose Wegovy
• Positive Sentiment: Chinese government official expressed support for Novo Nordisk’s continued presence and market cultivation in China—political goodwill could ease market access and reimbursement discussions in a major growth market. Reuters: China expresses hopes over Novo Nordisk’s presence in market
• Neutral Sentiment: Sanford C. Bernstein initiated coverage on NVO — could increase analyst attention and liquidity; impact depends on the firm’s stance and ratings (article linked). Sanford C. Bernstein Initiates Coverage on Novo Nordisk
• Neutral Sentiment: Rhythm Pharmaceuticals won an FDA approval for a rare genetic‑obesity therapy—limited overlap with Novo’s mass‑market GLP‑1 franchise, so competitive impact is minimal. Yahoo/Finance: Rhythm Grabs A New Obesity Approval
• Negative Sentiment: An FDA warning letter flagged deficiencies in Novo’s pharmacovigilance reporting for serious/unexpected adverse events for GLP‑1s (including Ozempic/Wegovy)—this raises regulatory scrutiny and potential compliance costs, which investors view negatively. Yahoo/Finance: FDA Letter Puts Novo Nordisk GLP-1 Risks And Valuation In Focus
• Negative Sentiment: Patent expiry for semaglutide in India opens the market to low‑cost generics (reports of Ozempic copies selling for ~$14) — this threatens international pricing and volume, particularly in large emerging markets. Financial Post: Ozempic Copies to Cost $14 in India
• Negative Sentiment: Competitive pressure from Eli Lilly’s next‑gen agents (retatrutide) and positive data for rivals are keeping investor concerns about market share and pricing intensity elevated. ProactiveInvestors: Lilly GLP-1 trial data and concerns
• Negative Sentiment: Semaglutide failed to show benefit in early Alzheimer’s at AD/PD 2026—this is a setback for potential label expansion beyond metabolic indications and reduces upside from new indications. Yahoo News: AD/PD 2026: semaglutide fails in early Alzheimer’s

Novo Nordisk A/S Price Performance

Shares of NYSE:NVO opened at $36.51 on Monday. The company’s fifty day moving average is $48.22 and its two-hundred day moving average is $51.07. The company has a market cap of $163.00 billion, a P/E ratio of 10.52 and a beta of 0.74. Novo Nordisk A/S has a 12-month low of $35.85 and a 12-month high of $81.44. The company has a quick ratio of 0.57, a current ratio of 0.80 and a debt-to-equity ratio of 0.61.

Novo Nordisk A/S (NYSE:NVO) last issued its earnings results on Tuesday, February 3rd. The company reported $1.01 EPS for the quarter, topping the consensus estimate of $0.90 by $0.11. Novo Nordisk A/S had a return on equity of 68.91% and a net margin of 33.03%.The business had revenue of $12.43 billion during the quarter, compared to analysts’ expectations of $11.97 billion. Equities analysts expect that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Novo Nordisk A/S Announces Dividend

The firm also recently disclosed a dividend, which will be paid on Wednesday, April 8th. Shareholders of record on Monday, March 30th will be given a dividend of $1.2751 per share. The ex-dividend date is Monday, March 30th. This represents a yield of 541.0%. Novo Nordisk A/S’s dividend payout ratio (DPR) is presently 23.63%.

Analysts Set New Price Targets

A number of research firms recently commented on NVO. BMO Capital Markets reiterated a “market perform” rating on shares of Novo Nordisk A/S in a research note on Thursday, February 5th. HSBC reaffirmed a “hold” rating and set a $54.00 price target on shares of Novo Nordisk A/S in a research note on Wednesday, December 10th. CICC Research began coverage on Novo Nordisk A/S in a research report on Friday, January 9th. They set an “outperform” rating and a $73.50 price target on the stock. The Goldman Sachs Group reissued a “neutral” rating and issued a $41.00 price objective (down from $63.00) on shares of Novo Nordisk A/S in a research note on Monday, March 2nd. Finally, Zacks Research upgraded Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a report on Tuesday, March 10th. Four analysts have rated the stock with a Buy rating, eighteen have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $65.56.

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.